LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against BioAge Labs, Inc. (“BioAge” or “the Company”) (NASDAQ: BIOA) for violations of the federal securities laws.

Investors who purchased the Company's securities pursuant and/or traceable to the Company’s initial public offering (“IPO”) conducted on September 26, 2024, are encouraged to contact the firm before March 10, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. BioAge announced on December 6, 2024, that it would discontinue its ongoing STRIDES Phase 2 trial of its lead trial candidate, azelaprag. The Company cited safety concerns in participants as the reason for the discontinuation, contrary to its claims during the IPO that azelaprag had potential in patients in obesity therapy with incretin drugs. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about BioAge, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108670692/en/